Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Prodencel in mCRPC
NCT05533203Phase 1Unknown
- Sponsor
- Shanghai Humantech Biotechnology
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Prodencel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Shanghai Humantech Biotechnology. Primary endpoint: Incidence of Treatment-Emergent Adverse Events (AEs) during Induction Immunization. Status: unknown.
02
Drugs
Prodencel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05533203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533203.